This site is intended for healthcare professionals

Additional data from 4 year update of ongoing phase 1/II study of valoctocogene roxaparvovec gene therapy for severe hemophilia A presented at World Federation of Hemophilia virtual summit.- BioMarin

Read time: 3 mins
Last updated:18th Jun 2020
Published:18th Jun 2020
Condition: Haemophilia A
Type: drug
Register free for full access to